PREvention of VENous ThromboEmbolism Following Radical Prostatectomy

• Status: Terminated
• Trial end date: 2019-11-01
• Target enrollment: 0
• Participant gender: Male

Summary

The PREVENTER Trial aims to compare the use of perioperative pharmacologic prophylaxis (subcutaneous heparin) with intermittent pneumatic compression devices (IPCs) to the use of IPCs alone for the prevention of venous thromboembolism (VTE) after radical prostatectomy (RP).

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Johns Hopkins University
• Treatments: Calcium heparin; Heparin

Criteria

Inclusion Criteria:

• Men 18-100 years of age with histologically confirmed prostate cancer of any stage undergoing RP

• Patients who would have otherwise been eligible to receive routine post-RP care

Exclusion Criteria:

• Active treatment for VTE

• Patients judged by patients' urologist, primary care doctor, or in the preoperative evaluation center (PEC) to be unsafe to forgo pharmacologic prophylaxis or systemic anticoagulation postoperatively (whether or not patients are on systematic anticoagulation for indications other than VTE)

• Known adverse reactions to heparin (heparin-induced thrombocytopenia or any allergy)

• Epidural analgesia

• Spinal anesthesia

• Participation in a different trial that increases a patient's risk of VTE